Journal of Contemporary Brachytherapy, published by TERMEDIA PUBLISHING HOUSE LTD, is a distinguished open-access journal dedicated to advancing the field of brachytherapy within the oncology and radiology domains. Since its inception in 2009, the journal has provided a platform for researchers, clinicians, and students to share innovative findings, cutting-edge techniques, and clinical experiences, contributing significantly to evidence-based practices in cancer treatment. With an ISSN of 1689-832X and E-ISSN 2081-2841, the journal has established its presence globally, and it is indexed in Scopus, achieving a commendable standing among its peers—with rankings of #196 in Radiology, Nuclear Medicine, and Imaging and #260 in Oncology for 2023. Notably, it holds a Q3 quartile classification, reflecting its emerging influence in these critical fields. The journal is committed to open science, ensuring that research is accessible to a wide audience, which is particularly vital for the ongoing development of methodologies and the implementation of best practices in brachytherapy. Exploring topics from the technical aspects of brachytherapy procedures to patient management strategies, the Journal of Contemporary Brachytherapy is an essential resource for those looking to stay at the forefront of oncological advancements.

Reports of Practical Oncology and Radiotherapy is a distinguished open-access journal dedicated to advancing the fields of oncology, radiotherapy, and cancer research. Published by VIA MEDICA since 2001, this journal serves as a critical platform for disseminating innovative research and practical findings that impact clinical practices and patient outcomes. With an emphasis on fostering collaboration and knowledge exchange among researchers, clinicians, and students, the journal has positioned itself within the Q3 and Q4 categories of renowned directories in oncology, radiology, and nuclear medicine as of 2023. Based in Gdansk, Poland, it provides unrestricted access to its articles, ensuring that crucial research reaches a wide audience. This dedication to open access reflects the journal's commitment to transparency and innovation in the fight against cancer, making it an invaluable resource in this vital field of study.

Radiotherapy and Oncology is a leading peer-reviewed journal published by Elsevier Ireland Ltd, focusing on the vital fields of hematology, oncology, and radiology. With an impressive impact factor and ranking in the top quartiles (Q1) of its categories as of 2023, it is recognized for disseminating high-quality research that contributes significantly to advancements in cancer treatment and patient care. The journal, which has been in circulation since 1983, aims to provide a platform for original research articles, reviews, and clinical studies that explore the latest innovations in radiotherapeutic technologies and oncology practices. This journal is essential for researchers, healthcare professionals, and students who are dedicated to improving cancer therapies and outcomes. Although it does not offer open access, the wealth of information contained within its pages supports continued education and development in these crucial medical fields.

Hepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

Physics & Imaging in Radiation Oncology is a premier journal dedicated to advancing the interdisciplinary field of radiation oncology through innovative research and imaging technologies. Published by Elsevier, this open-access journal has made its mark since its inception in 2017, ensuring that groundbreaking findings are accessible to a broad audience. With a strong focus on the integration of physics, imaging techniques, and oncology, the journal occupies esteemed positions in the academic landscape, ranking in the top quartile for Radiation and Radiology, Nuclear Medicine and Imaging as of 2023. The journal serves as a platform for researchers, professionals, and students to share insights and foster collaboration, ultimately improving patient outcomes through enhanced imaging and treatment modalities. Based in Ireland and operating from Radarweg 29, 1043 NX Amsterdam, Netherlands, the journal aims to bridge the gap between theoretical physics and practical applications in clinical settings.

Radiological Physics and Technology, published by SPRINGER JAPAN KK, is a prominent journal that serves as a crucial resource in the multidisciplinary fields of medicine and radiation sciences. With an ISSN of 1865-0333 and an E-ISSN of 1865-0341, the journal has been converging impactful research from 2008 to 2024. It holds a commendable position in academic rankings, currently classified in Q2 in Physical Therapy, Sports Therapy and Rehabilitation and Radiation, along with Q3 for Medicine (miscellaneous) and Radiology, Nuclear Medicine and Imaging. The journal is well-regarded in the academic community, reflected in its Scopus rankings that place it in the upper tiers of its respective categories. Although it currently does not offer Open Access, Radiological Physics and Technology remains a pivotal publication for researchers, academics, and practitioners seeking to advance knowledge and foster innovation in radiological science. Its commitment to disseminating high-quality research ensures its continued relevance and importance within these fields.

Cancer Radiotherapie, published by Elsevier, is a respected academic journal dedicated to advancing the field of oncology and radiology through original research and comprehensive reviews. With an ISSN of 1278-3218 and an E-ISSN of 1769-6658, the journal serves as a vital platform for disseminating knowledge and innovation in cancer treatment methodologies, specifically focusing on radiotherapy. As of 2023, it holds a Category Quartile of Q3 in both Oncology and Radiology, Nuclear Medicine and Imaging, reflecting its significance within these domains amidst a competitive landscape. Despite its current rankings—205th out of 333 in Radiology and 269th out of 404 in Oncology—it continuously strives to build a reputable presence with contributions that push the boundaries of cancer therapy. Although open access options are not available, the journal is committed to ensuring that valuable insights reach healthcare professionals and researchers worldwide, contributing to improved patient outcomes and advancements in treatment efficacy.

Brachytherapy, published by ELSEVIER SCIENCE INC, serves as a pivotal journal in the realms of Oncology and Radiology, Nuclear Medicine, and Imaging. With an ISSN of 1538-4721 and an E-ISSN of 1873-1449, the journal disseminates cutting-edge research and advancements from 2002 to 2024, focusing on the innovative field of brachytherapy. Although classified in the Q3 category for Oncology and Q2 for Radiology, Nuclear Medicine, and Imaging based on the 2023 quartile rankings, it continues to make significant contributions to clinical practice and methodology. Brachytherapy holds a respectable position in Scopus, ranking #155/333 and #234/404 in its respective categories, which reflects its importance and relevance to the scientific community. This journal is indispensable for researchers, healthcare professionals, and students looking to stay abreast of the latest techniques and therapeutic approaches in cancer treatment and imaging practices.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.